Concentra Group Holdings Parent, Inc 8-K, filed Nov 12, 2024
Concentra Group Holdings Parent, Inc. (CON)
About this 8-K
Concentra Group Holdings Parent, Inc filed this 8-K on November 12, 2024.
Items reported
- Item 7.01: Regulation FD disclosure
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
(Exact Name of Registrant as Specified in Its Charter)
(Commission File Number)
| (State or Other Jurisdiction of Incorporation) | (I.R.S. Employer Identification No.) |
(Address of principal executive offices) (Zip code)
(
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter):
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
| Item 7.01 | Regulation FD Disclosure. |
Attached as Exhibit 99.1 and furnished for purposes of Regulation FD is a presentation Concentra Group Holdings Parent, Inc. may use from time to time in presentations or discussions with investors, analysts and other parties after the date hereof in the fourth quarter of 2024.
The information in this Current Report on Form 8-K (including Exhibit 99.1) is being furnished solely to satisfy the requirements of Regulation FD and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
| Exhibit Number | Description | |
| 99.1 | Concentra Group Holdings Parent, Inc. Presentation. | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
| CONCENTRA GROUP HOLDINGS PARENT, INC. | ||
| Date: November 12, 2024 | By: | /s/ Michael E. Tarvin |
| Michael E. Tarvin | ||
| Executive Vice President and Secretary | ||
| ©2024 Concentra Inc. All rights reserved. Investor Presentation November 2024 |
| ©2024 Concentra Inc. All rights reserved. Disclaimer 2 Forward-Looking Statements This presentation contains forward-looking statements that express the Company’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results that include, but are not limited to, financial guidance and other projections and forecasts. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the Company’s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described in the Company’s filings with the Securities and Exchange Commission (“SEC”), including those under “Risk Factors” therein. Should one or more of these risks or uncertainties materialize, or should any of the assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Forward-looking statements speak only as of the date made. The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Use of Non-GAAP Financial Information In order to provide investors with greater insight, promote transparency and allow for a more comprehensive understanding of the information used by management in its financial and operational decision making, the Company supplements its condensed consolidated financial statements presented on a GAAP basis herein with certain non-GAAP financial information, including reconciliations of these non-GAAP measures to their most directly comparable GAAP measures, which are included in this presentation, as well as in the Company’s quarterly financial press releases and related Form 8-K filings with the SEC. This information can be accessed for free by visiting www.concentra.com or www.sec.gov. We believe that the presentation of Adjusted EBITDA and Adjusted EBITDA margin, as defined herein, are important to investors because Adjusted EBITDA and Adjusted EBITDA margin are commonly used as an analytical indicator of performance by investors within the healthcare industry. Adjusted EBITDA and Adjusted EBITDA margin are used by management to evaluate financial performance of, and determine resource allocation for, each of our operating segments. However, Adjusted EBITDA and Adjusted EBITDA margin are not measures of financial performance under U.S. GAAP. Items excluded from Adjusted EBITDA and Adjusted EBITDA margin are significant components in understanding and assessing financial performance. Adjusted EBITDA and Adjusted EBITDA margin should not be considered in isolation, or as an alternative to, or substitute for, net income, net income margin, income from operations, cash flows generated by operations, investing or financing activities, or other financial statement data presented in the consolidated financial statements as indicators of financial performance or liquidity. Because Adjusted EBITDA and Adjusted EBITDA margin are not measurements determined in accordance with U.S. GAAP and are thus susceptible to varying definitions, Adjusted EBITDA and Adjusted EBITDA margin as presented may not be comparable to other similarly titled measures of other companies. We define Adjusted EBITDA as earnings excluding interest, income taxes, depreciation and amortization, gain (loss) on early retirement of debt, stock compensation expense, separation transaction costs, gain (loss) on sale of businesses, and equity in earnings (losses) of unconsolidated subsidiaries. We define Adjusted EBITDA margin as Adjusted EBITDA divided by revenue. We will refer to Adjusted EBITDA and Adjusted EBITDA margin throughout these materials. |
| ©2024 Concentra Inc. All rights reserved. COMPANY OVERVIEW |
| ©2024 Concentra Inc. All rights reserved. Concentra At-a-Glance (1) As of September 30, 2024; (2) As of CY 2023; (3) The term "colleagues and affiliated physicians and clinicians" includes both our directly employed colleagues who provide administrative and management support to the affiliated professional medical group entities and the physicians and clinicians that are employed by the affiliated professional medical groups; (4) Adjusted EBITDA and Adjusted EBITDA margin are non-GAAP measures, see appendix for a reconciliation to net income; (5) Average of 2020-2023, calculated as free cash flow (“FCF”) divided by Adjusted EBITDA, FCF is calculated as Adjusted EBITDA minus purchases of property and equipment, and is a non-GAAP measure; (6) TTM is a non-GAAP measure. See the Appendix for a reconciliation of TTM 4 Concentra is the largest provider of occupational health services in the United States by number of locations1 , with a mission of improving the health of America’s workforce, one patient at a time. KEY STATISTICS 156 Onsite health clinics1 ~11k Total colleagues & affiliated clinicians2,3 $1.9bn TTM Revenue1,6 19.6% TTM Adj. EBITDA margin1,4,6 45 States with service offerings1 200k+ Employer customers2 50,000+ Patients cared for each business day2 ROBUST FINANCIALS $368mm TTM Adj. EBITDA1,4,6 <1% Revenue from government payor reimbursement1 >80% Free cash flow conversion5 ©2024 Concentra Inc. All rights reserved. 549 Occupational health centers1 <3% Revenue from largest employer customer1 |
| ©2024 Concentra Inc. All rights reserved. We Have Built an Extensive Footprint Across the U.S. (1) As of December 31, 2023; (2) Comprised of 19 states that have an annual automatic update, using different inflationary indicators for those increases (e.g., MEI/Medicare Economic Index, CPI, Average Weekly Wages), on an annual or bi-annual basis 5 Our broad geographic footprint serves a vast number of employers and enables us to care for millions of employees 65% of U.S. employer locations are within ~12 miles of our health centers1 Occupational Health Center Onsite Health Clinic Telemedicine Presence Only |
| ©2024 Concentra Inc. All rights reserved. We Create Convenient Access for Employers and Patients… 6 (1) As of September 30, 2024; (2) TTM as of September 30, 2024, figures are rounded, remaining ~2% comprised of other businesses (pharmacy repackaging operations and third-party employer services administration) Occupational Health Centers Onsite Health Clinics Telemed Description Centers specializing in offering occupational and other health care services to employer customers Clinics dedicated to a single employer’s worksite, offering occupational health, advanced primary care, and other services Telemedicine solution used to treat work injuries and illnesses, behavioral health, and other services # of Facilities1 549 156 Virtual 24/7 Customer Types 200,000+ employers, ranging from Fortune 100 to small businesses Medium to large-sized companies All types of employers % of Revenue2 ~94% ~3% ~1% Services Offered Occupational Health (Workers’ Compensation, Employer Services), Consumer Health and Advanced Primary Care ©2024 Concentra Inc. All rights reserved. 6 |
| ©2024 Concentra Inc. All rights reserved. … And Offer a Comprehensive Array of Services For Workers’ Compensation and Employer Services, All in One Place 7 Nature of injuries treated Sprains / strains Lacerations / abrasions Eye injuries Burns / wound care Exposures Fractures Select services offered Drug and alcohol screens Immunizations Physical examinations Lab services Vision testing Performance evaluations Workers’ Compensation Services Employer Services (1) Occupational Health Center revenue, TTM as of September 30, 2024; remaining ~2% of revenue comprised of Urgent Care/Commercial/Medicare/Other ~64% Of Revenue1 ~34% Of Revenue1 Other tests / screens Physical examinations Drug and alcohol screens Injury care Physical therapy Specialty care |
| ©2024 Concentra Inc. All rights reserved. Our Value Proposition is Focused on Improving Employees’ Health with a Safe Return to Work (1) Seen by Concentra for the year ended December 31, 2023; (2) Claim studies conducted by Concentra are based on approximately 500,000 closed claims evaluated between 2020 and 2023 for a select number of Concentra customers, including employers and a worker's compensation insurance carrier; (3) Based on over 1 million survey reports received annually; (4) Based on Google review scores of ~540 centers for CY 2023 8 With alignment across all stakeholders – including patients, employers, and payors – we aim to ensure employees’ safe and sustainable return to work and help lower overall claims costs, all while providing the highest quality care and experience possible Access and convenience High-quality health care and positive clinical outcomes Excellent customer experience with strong communication Early clinical intervention and safe and sustainable return to work Strong process management, technologies, and innovation Strong outcomes for employers… … High quality experience for employees Of injured employees are recommended for return to work in some capacity on same day after initial visit1 95% Of patients rate Concentra a 9 or 10, on a scale of 1-10, on overall satisfaction with their occupational health center visit3 ~77% On a rating scale of 1-5 stars on nationwide google reviews; 72% of centers rated 4 stars or above4 4.1 Lower average total cost per claim2 (compared to non-Concentra health centers) 25% |
| ©2024 Concentra Inc. All rights reserved. We Serve a Deep and Diverse Customer Base… 9 Major ecosystem partners have been with us for 20+ years on average1 Workers’ compensation and employer services ecosystem partners Insurance carriers and third-party claims and employer services administrators Representative insurance carriers and TPAs Employers 200k employer customers1 Representative employer customers Top 1,000 employer customers represent ~37% of revenue2 99% of top 100 employer customers have been with us for 10+ years1 100% of Fortune 100 companies1 (1) As of December 31, 2023; (2) For the twelve months ended September 30, 2024 |
| ©2024 Concentra Inc. All rights reserved. … with Diversity Across Payors, Geographies, Industries and Employer Customers (1) Occupational Health Center revenue, TTM as of September 30, 2024; (2) Based on occupational health centers operated by Concentra as of September 30, 2024. Percentages represent rounded approximations and may 10 not total 100% Broad geographic mix2 Remaining States 55% California 18% Texas 10% Florida 6% Pennsylvania 6% Colorado 5% Attractive payor mix1 ~99% Non-government payor Employer Services Employers and TPAs 34% Medicare & Other <1% Workers’ Compensation Employers, insurance carriers and TPAs 64% Urgent & Commercial 2% Diverse industry mix1 Manufacturing, 9% Business Services & Staffing Agencies, 8% Retail, 8% Healthcare, 8% Food Stores, Products & Restaurants, 8% Government, 7% Logistics & Motor Freight, 7% Transportation, 7% Construction, 7% Wholesale, 7% Schools, 4% Other, 20% Low employer customer concentration1 37% Top 1,000 Employers Remaining Employers 63% #2 - #1,000 Employers 34% #1 Employer 3% |
| ©2024 Concentra Inc. All rights reserved. Our Industry Has Seen Stable Growth Over Time… (1) U.S. Bureau of Labor Statistics; (2) Represents 2022 figures, according to the U.S. Bureau of Labor Statistics; (3) Represents average Concentra growth in visit-related incremental revenue from reimbursement rates 11 across workers’ compensation and employer services based on Concentra data; (4) As of October 2024 Consistent reimbursement rate increases Stabilizing workplace injury incidence A growing active U.S. workforce U.S. workforce size (millions)1 Top 10 industries by injury incidence2 Annual growth in incremental revenue from reimbursement rates (YoY%)3 4.9% 4.8% 4.2% 4.1% 3.7% 3.2% 2.9% 2.6% 2.4% 1.8% State & Local Government Transportation & Warehousing Educational & Health Services Agriculture, Forestry, Fishing & Hunting Retail Trade Manufacturing Leisure, Entertainment & Hospitality Wholesale Trade Construction Other Services 151 160 2019 2024 2016 2023 ~6% increase ~3% CAGR 4 |
| ©2024 Concentra Inc. All rights reserved. … Driven by Ongoing Workforce Needs and Challenges (1) Bain & Company; (2) Since 2000; National Council on Compensation Insurance; (3) Travelers study, based on indemnity claim data in 2016-2020 accident years; (4) In 2009, according to the Occupational Safety and Health Administration; (5) MedRisk; (6) In 2022, according to The National Safety Council. Includes wage and productivity losses of $50.7 billion, medical expenses of $37.6 billion, administrative expenses of $54.4 billion, employers’ uninsured costs of $15.0 billion, damage to motor vehicles in work-related injuries of $5.6 billion and fire losses of $3.7 billion; (7) Includes wage and productivity losses of $50.7 billion, administrative expenses of $54.4 billion, employers’ uninsured costs of $15.0 billion, damage to motor vehicles in work-related injuries of $5.6 billion and fire losses of $3.7 billion 12 High injury rates among young workers 28% Of claims attributable to manufacturing employees with <1 year experience3 Aging employed population 25-30% Of U.S. employees projected to be over age 55 by 20301 Prevalence of depression and anxiety 50% Of injured employees experience clinically-related depressive symptoms5 Inadequate cost-effective solutions $167bn Total cost of work-related injuries in 2022 in the U.S.6 Widespread hazardous exposures 40mm Employees potentially exposed to hazardous chemicals in the workplace4 Increase in comorbidity claims 175% Increase in workers’ compensation claims involving comorbidities2 $167bn Medical Expenses Other Expenses7 • Wage and Productivity Losses • Administrative Expenses • Employers’ Uninsured Costs • Other Losses ~$129bn (~77% of total) ~$38bn (~23% of total) |
| ©2024 Concentra Inc. All rights reserved. We Are Delivering On Our Objectives, and It’s Just The Beginning 13 What we have achieved Executing On Our Base Business Stable enterprise-wide top-line growth and attractive ~20% Adj. EBITDA margins, with opportunity for future upside from growth initiatives Building Our Growth Pipeline Continued build-out of our organic growth pipeline with 8 signed leases for de novos over the next 12 months, with a robust acquisition pipeline Successful key hires made to support a seamless transition; on track for On Track for Our Separation full operational independence by the end of 2026 Announced a $0.0625 dividend per share in Q3’24; on track to delever from ~3.9x at IPO to 3.5 to 3.6x by the end of 2024 Prudent Capital Allocation Launch of new services (telemed-based behavioral health; advanced primary care) and roll-out of new technologies driving efficiencies Expanding Services and Technologies |
| ©2024 Concentra Inc. All rights reserved. Our Competitive Strengths Deliver Value Creation 14 1 Leader in Occupational Health Services 6 Track Record of Innovation 7 Multiple Levers Driving Robust Growth 8 Experienced Leadership 3 High-Quality Health Care & Positive Clinical Outcomes 2 Diversified Service Offering 4 Operational Excellence & Positive Patient Satisfaction 5 Deep & Diverse Customer Relationships |
| ©2024 Concentra Inc. All rights reserved. FINANCIAL UPDATE |
| ©2024 Concentra Inc. All rights reserved. • Number of locations grew 3.1% YoY to 705 total locations • Opened one de novo (Chattanooga, TN) and completed one acquisition (Chicago, IL) • Revenue increased 3.3% in Q3 YoY • Largely driven by stable workers’ compensation visit volume and reimbursement rate increases across visit types, more than offsetting the decline of the lower revenue-per-visit employer services volume • Adjusted EBITDA grew 2.7% YoY, largely a result of revenue growth as well as improved efficiencies around general and administrative expense • Capital expenditures (excluding acquisitions) totaled $15.1 million in Q3 • Dividend approved by Board of Directors ($0.0625 per share), payable November 22, 2024 16 Key Q3 Performance Highlights & Company Developments Q3 ’23 Q3 ’24 YoY (∆) Facility Count (End of Period) Total Occupational Health Centers 539 549 +10 Total Onsite Health Clinics 145 156 +11 KPIs Visits per Day (“VPD”) 52.1k 50.9k (2.2%) Revenue per Visit (“RPV”) $136.11 $141.42 3.9% Financials ($ in millions) Total Revenue $474.0 $489.6 3.3% Total Adj. EBITDA $98.9 $101.6 2.7% % margin 20.9% 20.7% (12bps) Capital Expenditure $15.5 $15.1 (2.0%) |
| ©2024 Concentra Inc. All rights reserved. YTD 2024 Performance (1) Adjusted EBITDA and Adjusted EBITDA margin are non-GAAP measures, see appendix for a reconciliation to net income 17 539 549 145 156 684 705 9/30/23 9/30/24 Centers Onsites +2% +8% +3% 22,391 22,733 27,836 26,513 51,136 50,149 YTD '23 YTD '24 Work. Comp. Empl. Svcs. Cons. Health +2% -5% -2% $1,397.3 $1,435.2 YTD '23 YTD '24 +3% Revenue ($mm) $293.0 $299.3 YTD '23 YTD '24 +2% Adjusted EBITDA1 ($mm) 21.0% 20.9% YTD '23 YTD '24 -10bps Adjusted EBITDA Margin1 $134.62 $140.12 YTD '23 YTD '24 +4% Work. Comp. Empl. Svcs. $195 $86 $199 $90 +2% +4% Number of Locations Visits per Day Revenue per Visit |
| ©2024 Concentra Inc. All rights reserved. Balance Sheet & Capital Allocation Strategy (1) Net Leverage = Net Debt / Adjusted EBITDA (per credit facility leverage calculation, non-GAAP measure); (2) $400M revolver undrawn, except $14M of normal course letters of credit that were in place at time of IPO/refinancing 18 Capital Allocation Strategy Leverage Prudent management of leverage levels, targeting <3.0x net leverage 24 months post-IPO M&A and De Novos Strong pipeline + disciplined approach to enhancing footprint for short- and long-term value creation Capital Expenditures Continued strategic investment in technology, facilities, and infrastructure Dividend Concentra Board of Directors approved a dividend of $0.0625 per share Net Leverage1 ~3.9x 3.7x <3.0x IPO Launch 9/30/2024 24-Month Target Post-IPO Liquidity ($mm) $137 $386 $523 9/30/2024 Cash Revolver Capacity2 |
| ©2024 Concentra Inc. All rights reserved. 2024 Full-Year Guidance (1) Adjusted EBITDA is a non-GAAP measures, see appendix for a reconciliation to net income; (2) Net Leverage = Net Debt / Adjusted EBITDA (per credit facility leverage calculation, non-GAAP measure); (3) Year-over-year change calculated using the mid-point of FY 2024 outlook, where applicable 19 Total Revenue Adjusted EBITDA1 Capital Expenditures Net Leverage2 FY 2024 Outlook ~$1.9bn $370mm – $375mm $65mm – $70mm 3.5x – 3.6x FY 2023 Actual $1.8bn $361mm $65mm N/A |
| ©2024 Concentra Inc. All rights reserved. Our Long-Term Financial Targets (1) Adjusted EBITDA and Adjusted EBITDA margin are non-GAAP measures; (2) Calculated as free cash flow (“FCF”) divided by Adjusted EBITDA, FCF is calculated as Adjusted EBITDA minus purchases of property and equipment, and is a non-GAAP measure; (3) Net Leverage = Net Debt / Adjusted EBITDA (non-GAAP measure, see appendix for a reconciliation of Adjusted EBITDA to net income) 20 Consistent Profitability with Continued Improvement 20%+ Adjusted EBITDA margin1 Robust Free Cash Flow2 Generation >80% Annual FCF conversion2 Prudent Deleveraging Strategy < 3.0x Targeted net leverage in 24 months vs. 3.9x upon IPO launch3 Stable Revenue Growth (Further Upside from De Novos and M&A) Mid-to-High Single-digit growth Dividend $0.0625 Cash dividend per share Note: These are not projections; they are goals/targets and are forward-looking, subject to significant business, economic, regulatory and competitive uncertainties and contingencies, many of which are beyond the control of the Company and its management, and are based upon assumptions with respect to future decisions, which are subject to change. Actual results will vary and those variations may be material. Nothing in this presentation should be regarded as a representation by any person that these goals/targets will be achieved and the Company undertakes no duty to update its goals/targets |
| ©2024 Concentra Inc. All rights reserved. APPENDIX |
| ©2024 Concentra Inc. All rights reserved. Our Experienced Leadership Team with 275 Years of Combined Experience with Concentra 22 MATTHEW DICANIO President & Chief Financial Officer ▪ Joined Concentra in 2015 ▪ 20+ years of experience in management, finance and M&A ▪ Tenure: 9 years WILLIAM K. NEWTON Chief Executive Officer ▪ Joined Concentra (formerly known as OccuSystems) in 1995 ▪ 40+ years of experience in healthcare business ▪ Tenure: 25 years JOHN DELORIMIER Executive Vice President, Chief Digital & Data Officer Tenure: 16 years DANIELLE KENDALL Senior Vice President, Human Resources Tenure: 24 years JONATHAN CONSER Executive Vice President, Chief Growth & Customer Officer Tenure: 21 years DOUGLAS MCANDREW Executive Vice President, Chief Operating Officer – West Tenure: 30 years GIOVANNI GALLARA, PT Executive Vice President, Chief Clinical Services Officer Tenure: 13 years JOHN ANDERSON, DO Executive Vice President, Chief Medical Officer Tenure: 31 years GREG GILBERT Executive Vice President, Chief Reimbursement & Government Relations Officer Tenure: 30 years SU ZAN NELSON Executive Vice President, Chief Accounting Officer Tenure: 21 years MICHAEL KOSUTH Executive Vice President, Chief Operating Officer – East Tenure: 28 years MICHAEL RHINE Executive Vice President, Chief Operating Officer Onsite Health & Telemedicine Tenure: 21 years THOMAS DEVASIA Executive Vice President, Chief Marketing & Innovation Officer Tenure: 8 years TIM RYAN Executive Vice President, General Counsel Tenure: Joined Oct. 2024 |
| ©2024 Concentra Inc. All rights reserved. Introducing our Board of Directors with a Long Track Record of Success and Health Care Leadership Experience 23 Robert A. Ortenzio Director, Chair • Co-founder and Executive Chairman/Director of Select Medical • Previously served as Select Medical’s CEO, President and COO • Former executive roles with Horizon/CMS Healthcare Corporation, Continental Medical Systems (including as co-founder) and Rehab Hospital Services Corporation Daniel J. Thomas Director Keith Newton Director, CEO Cheryl Pegus, MD, MPH Director Marc R. Watkins, MD Director • Former Concentra President, CEO and COO from 1993 through 2007 • Director of Select Medical, Healthcare Highways, National Partners in Healthcare and Equalis Group; previously served on the board of AccentCare • Former executive roles with National Partners in Healthcare, Provista and Viant • Has served as Concentra’s CEO since 2015 • Formerly Concentra’s Chairman of the Board of Directors from 2018 to 2022; initially joined Concentra’s predecessor, OccuSystems, in 1995 • Former executive roles with DentalOne Partners and Columbia HCA’s Ambulatory Surgery Division, as well as accounting and finance roles at The Associates First Capital Corporation and KPMG Peat Marwick • Currently serves as a board member for Boston Scientific • Formerly served as a cardiovascular-focused medical director at Pfizer, partner at Morgan Health, Executive Vice President of Health and Wellness at Walmart, and Chief Medical Officer at Symcare Personalized Health Solutions and at Walgreens Company • Previously a cardiologist, clinical researcher and fellow at The Joan & Sanford I. Weill Medical College of Cornell University and Memorial Sloan Kettering Cancer Center • Chief Medical Officer of Kroger Health since 2018 • Previously served 5+ years in senior medical oversight roles at Concentra, as well as Interim Medical Director for the North American division of Nissan Motor Co. • Previously served as senior medical officer at a US Marine Corps Station, as well as group surgeon of Camp Al Asad in Iraq • Former adjunct professor in the pharmacy department of the University of Cincinnati |
| ©2024 Concentra Inc. All rights reserved. Reconciliation of Net Income to Adjusted EBITDA and TTM Revenue 24 Three Months Ended Sep. 30, Nine Months Ended Sep. 30, Three Months Ended Dec. 31, TTM Sep. 30, ($000's) 2024 2023 2024 2023 2023 2024 Revenue $489,638 $473,964 $1,431,151 $1,397,341 $440,740 $1,871,891 Net Income $45,759 $54,424 $149,097 $155,887 $28,856 $177,953 Income Tax Expense $16,415 $15,205 $49,648 $47,964 $9,923 $59,571 Interest Expense $21,369 $64 $21,275 $108 $115 $21,390 Interest Expense on Related Party Debt $2,691 $11,255 $21,980 $33,831 $10,422 $32,402 Equity in Losses of Unconsolidated Subsidiaries - - $3,676 $526 - $3,676 Stock Compensation Expense $168 - $500 $178 $473 $973 Depreciation and Amortization $15,213 $17,959 $51,568 $54,552 $18,499 $70,067 Separation Transaction Costs ($44) - $1,569 - - $1,569 Adjusted EBITDA $101,571 $98,907 $299,313 $293,046 $68,288 $367,601 |
| ©2024 Concentra Inc. All rights reserved. Reconciliation of 2024 Full-Year Adjusted EBITDA Guidance 25 Range ($ in millions) Low High Net Income $169 $173 Income Tax Expense $57 $58 Interest Expense $22 $22 Interest Expense on Related Party Debt $48 $48 Equity in Losses of Unconsolidated Subsidiaries $4 $4 Stock Compensation Expense $1 $1 Depreciation and Amortization $67 $67 Separation Transaction Costs $2 $2 Adjusted EBITDA $370 $375 |
|
